Core Viewpoint - The stock price of Yuan Da Pharmaceutical (00512) surged over 7% ahead of its earnings announcement, reflecting positive market sentiment following the FDA approval of its radioactive product for treating unresectable hepatocellular carcinoma (HCC) [1] Company Developments - Yuan Da Pharmaceutical plans to hold a board meeting on August 19 to approve its interim results [1] - The company announced that its yttrium-90 microsphere injection has received FDA approval for a new indication, making it the first and only selective internal radiation therapy product approved for both unresectable HCC and colorectal cancer liver metastases [1] - The company has established a complete industrial chain in the nuclear medicine sector, with its core product, Yttrium-90 microsphere injection, rapidly gaining market traction since its domestic approval in 2022 [1] Market Performance - As of the report, Yuan Da Pharmaceutical's stock rose by 6.92%, trading at 8.96 HKD with a transaction volume of 283 million HKD [1] - Tianfeng Securities noted that the product has treated nearly 2,000 patients by the end of 2024, projecting sales revenue of nearly 500 million RMB for that year [1] Future Outlook - The company aims to build a comprehensive layout in tumor interventional therapy and the RDC platform, actively advancing multiple nuclear medicine products in clinical research [1] - The firm is expected to enter an accelerated development phase, supported by its innovative product offerings and market positioning [1]
港股异动 | 远大医药(00512)尾盘涨超7% 今日盘后将发中期业绩 机构看好公司进入加速发展阶段